|
|
Article: Cangene Gets $143M HHS Contract For Anthrax Drug.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Two months after getting a $362 million contract for its botulism treatment under the U.S. government's Project BioShield, Canadian firm Cangene Corp. has added a separate deal, valued at $143.8 million, for its anthrax product.
The Department of Health and Human Services exercised its option from a September 2005 agreement to purchase, over a three-year period, 10,000 doses of Cangene's anthrax immune globulin (AIG). That decision followed the completion of successful preliminary efficacy testing of the drug.
AIG, an antibody derived from donors immunized with the anthrax vaccine, is a hyperimmune product designed to treat ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|